Article

NSAID plus steroid better than steroid alone

Ketorolac tromethamine 0.4% (Acular LS, Allergan) plus steroid improves the visual outcome following uncomplicated cataract surgery by reducing the incidence of retinal thickening, according to a recent multicenter study. This combination therapy also reduces the incidence of cystoid macular edema. These findings suggest that this therapy would be beneficial in all cataract surgery cases.

"This study indicates that ketorolac tromethamine 0.4% should be used pre- and postoperatively in every patient undergoing cataract surgery because we want to reduce the patient's risk of any macular thickening at all. It eliminates the risk of CME, even in low-risk patients," said John R. Wittpenn Jr., MD, Ophthalmic Consultants of Long Island, Stony Brook, NY.

This new study is more evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) are beneficial in cataract surgery. Previous studies have shown that patients receiving diclofenac sodium ophthalmic solution 0.1% (Voltaren, Novartis) after cataract surgery had less CME-as measured by optical coherence tomography [OCT]-than patients receiving steroids only, demonstrating that NSAIDs are beneficial in uneventful cataract surgery, he said. NSAIDs selectively block formation of prostaglandins following surgical trauma and are active against macular leakage initiated by a prostaglandin cascade triggered by surgery.

Many have argued, however, that this two-pronged approach should be reserved for patients at high risk of CME, such as those with diabetic macular edema, vascular disease, or other macular problems, he continued.

To learn more about NSAIDs and steroids in patients undergoing cataract surgery, Dr. Wittpenn and colleagues designed a randomized, investigator-masked, multicenter study to compare ketorolac plus steroid with steroid alone.

The key inclusion criteria were individuals who were aged 18 years or more scheduled to undergo cataract surgery with surgeon expectations of 20/20 best-corrected visual acuity postoperatively. Patients with risk factors for CME, such as a history of macular or vascular problems, iritis, or uveitis, were excluded, because the objective was to have uneventful surgery, Dr. Wittpenn explained. If difficulties or complications such as vitreous loss arose, the surgeon could discontinue patients from the study during surgery or postoperatively.

Do NSAIDs make difference?

"The patients who come through this study should be what I like to call the best of the best," he said. "They should have no macular problems, 20/20 vision, and a straightforward postoperative course. We wanted to see if, in that situation, in the lowest-risk or supposed no-risk patients, the NSAIDs would make a difference. If they made a difference in this group of patients, then I would expect them to make a clear difference in the patients who are at a higher risk of CME."

In this study, 546 patients scheduled to undergo cataract surgery were randomly assigned to one of two groups in a 1:1 ratio. Group 1 received ketorolac q.i.d. for 3 days before surgery and four doses during dilation immediately before the procedure. These patients continued to use ketorolac q.i.d. postoperatively until they exited the study, and they also instilled prednisolone acetate ophthalmic suspension 1% (Pred Forte, Allergan) q.i.d. from a 5-ml bottle until it was empty.

Group 2 received an artificial tear solution for 3 days before surgery and ketorolac only during dilation. After surgery, these patients continued to use artificial tears until the 5-ml bottle was empty and instilled prednisolone q.i.d. from two 5-ml bottles until leaving the study.

Both groups received gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) q.i.d. for 3 days prior to surgery and every 15 minutes in the hour before surgery. They continued to use the antibiotic four times daily after surgery until the surgeon determined that the risk of infection had passed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.